KRAS and colorectal carcinoma: Finally, although performed on a limited number of CRC cases, our preliminary data seemed to indicate no correlation between PIK3CA mutations and response to the anti-EGFR treatment in patients with wild-type KRAS (objective responses were considered at first evaluation only) (see Table 5).